| NCT ID | NCT05008081 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wim Janssens |
| Condition | Chronic Obstructive Pulmonary Disease Exacerbation |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-10-25 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2022-10-25 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.
Eligibility Criteria
Inclusion Criteria: * Age 18 years and older * Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test with an FEV1/FVC \< 0.7) * Current hospitalization with suspicion of an acute exacerbation of COPD (AECOPD) * Inclusion within 48 hours post hospital admission * Voluntary written informed consent of the participant or his/her representative obtained prior to any study procedure Exclusion Criteria: * Patients unwilling or unable to comply with study procedures * Patients not requiring treatment with systemic corticosteroids, antibiotics or both as a minimum therapy for the index AECOPD * Patients with a confirmed positive test result for COVID19, or those highly suspected based on clinical examination
Contact & Investigator
Wim Janssens, MD, PhD
STUDY CHAIR
UZ/KU Leuven - Belgium
Frequently Asked Questions
Who can join the NCT05008081 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Obstructive Pulmonary Disease Exacerbation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05008081 currently recruiting?
Yes, NCT05008081 is actively recruiting participants. Contact the research team at kristina.vermeersch@kuleuven.be for enrollment information.
Where is the NCT05008081 trial being conducted?
This trial is being conducted at Linz, Austria, Vienna, Austria, Brussels, Belgium, Leuven, Belgium and 11 additional locations.
Who is sponsoring the NCT05008081 clinical trial?
NCT05008081 is sponsored by Wim Janssens. The principal investigator is Wim Janssens, MD, PhD at UZ/KU Leuven - Belgium. The trial plans to enroll 1,000 participants.